Quarterly report · Q3
2914.TEDINET S100PFP4
Period2022-01-01 → 2022-09-30
Filed2022-10-31
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.01T | 2022-01-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥741.7bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥2.32T | 2021-01-01 → 2021-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.77T | 2021-01-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥621.5bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥579.3bn | 2022-01-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥196.4bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥480.7bn | 2021-01-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥158.6bn | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥535.6bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥174.6bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥472.4bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥463.8bn | 2021-01-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥149.7bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥403.8bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥139.7bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥338.5bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥338.8bn | 2021-01-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥113.6bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥403.9bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥138.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥340.2bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥340.3bn | 2021-01-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥114.3bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥6.73T | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥5.77T | at 2021-12-31 | Cons. | Assets IFRS |
| Total assets | ¥5.63T | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.86T | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.89T | at 2021-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥3.87T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.89T | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.87T | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.60T | at 2020-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥3.79T | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.81T | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥778.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥721.7bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥630.7bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥538.8bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥343.6bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥598.9bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥428.9bn | 2021-01-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥70.0bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥97.5bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥70.1bn | 2021-01-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥357.4bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥353.1bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥291.3bn | 2021-01-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥227.53 | 2022-01-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥78.74 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥190.76 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥190.95 | 2021-01-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥64.03 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥227.45 | 2022-01-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥78.71 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥190.68 | 2021-01-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥190.87 | 2021-01-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥64 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 56.3% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.6% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.6% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 136
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-01-01 → 2022-09-30 | ¥8.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-07-01 → 2022-09-30 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-01-01 → 2022-09-30 | ¥1.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-07-01 → 2022-09-30 | ¥440m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥6.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥643m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-09-30 | −¥24.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-09-30 | −¥24.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-09-30 | −¥22.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-07-01 → 2022-09-30 | −¥8.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-07-01 → 2022-09-30 | −¥8.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-07-01 → 2022-09-30 | −¥10.1bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-09-30 | −¥7.1bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥721m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-09-30 | −¥7.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥721m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-09-30 | −¥48m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-09-30 | −¥48m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-09-30 | −¥48m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥1m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥1m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥1m |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥59.7bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥20.4bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥59.7bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥20.4bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥7.3bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥7.3bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥7.3bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥112.8bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥39.3bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥112.8bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥39.3bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥722m |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥409m |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥409m |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥306m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥1.83T |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥681.7bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥1.83T |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥681.6bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥215m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥77m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥653.5bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥653.5bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥594.1bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥228.3bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥228.3bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥203.7bn |
| —segment total | revenue | 2022-01-01 → 2022-09-30 | ¥2.01T |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥741.4bn |
| —segment total | revenue external | 2022-01-01 → 2022-09-30 | ¥2.01T |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥741.3bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥215m |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥78m |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥662.6bn |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥662.6bn |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥602.0bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥231.1bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥231.1bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥206.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-01-01 → 2021-09-30 | ¥5.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-07-01 → 2021-09-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-01-01 → 2021-09-30 | ¥1.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-07-01 → 2021-09-30 | ¥588m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-01-01 → 2021-09-30 | ¥3.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-01-01 → 2021-09-30 | −¥28.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-01-01 → 2021-09-30 | −¥28.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-01-01 → 2021-09-30 | −¥25.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-07-01 → 2021-09-30 | −¥9.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-07-01 → 2021-09-30 | −¥9.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-07-01 → 2021-09-30 | −¥6.0bn |
| Reconciling Itemsreconciling | revenue | 2021-01-01 → 2021-09-30 | −¥4.1bn |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-09-30 | −¥1.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-01-01 → 2021-09-30 | −¥4.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-09-30 | −¥1.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-09-30 | −¥79m |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-09-30 | −¥79m |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-09-30 | −¥79m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-09-30 | −¥25m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-09-30 | −¥25m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-09-30 | −¥25m |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue | 2021-01-01 → 2021-09-30 | ¥56.8bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥19.7bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue external | 2021-01-01 → 2021-09-30 | ¥56.8bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥19.7bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥6.6bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥6.6bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥6.8bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue | 2021-01-01 → 2021-09-30 | ¥106.7bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥36.2bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue external | 2021-01-01 → 2021-09-30 | ¥106.7bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥36.2bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue intersegment | 2021-01-01 → 2021-09-30 | ¥0 |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥0 |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥2.4bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥2.4bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥904m |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥904m |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥847m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue | 2021-01-01 → 2021-09-30 | ¥1.60T |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥565.1bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue external | 2021-01-01 → 2021-09-30 | ¥1.60T |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥565.0bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue intersegment | 2021-01-01 → 2021-09-30 | ¥232m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥82m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥562.9bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥562.9bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥498.4bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥190.2bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥190.2bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥160.7bn |
| —segment total | revenue | 2021-01-01 → 2021-09-30 | ¥1.76T |
| —segment total | revenue | 2021-07-01 → 2021-09-30 | ¥621.0bn |
| —segment total | revenue external | 2021-01-01 → 2021-09-30 | ¥1.76T |
| —segment total | revenue external | 2021-07-01 → 2021-09-30 | ¥620.9bn |
| —segment total | revenue intersegment | 2021-01-01 → 2021-09-30 | ¥232m |
| —segment total | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥82m |
| —segment total | segment profit | 2021-01-01 → 2021-09-30 | ¥571.8bn |
| —segment total | segment profit | 2021-01-01 → 2021-09-30 | ¥571.8bn |
| —segment total | segment profit | 2021-01-01 → 2021-09-30 | ¥506.6bn |
| —segment total | segment profit | 2021-07-01 → 2021-09-30 | ¥194.1bn |
| —segment total | segment profit | 2021-07-01 → 2021-09-30 | ¥194.1bn |
| —segment total | segment profit | 2021-07-01 → 2021-09-30 | ¥164.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,100
| Item | Context | Value | Unit |
|---|---|---|---|
| Intersegment revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -4073000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration | - | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 1601384000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 56781000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 106655000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1764820000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 5328000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -4073000000 | JPY |
| Revenue IFRS | Prior1YTDDuration | 1766075000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 562875000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 6608000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 2357000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 571840000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -28873000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -79000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration | 542888000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 1834539000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 59665000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 112798000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 2007001000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1547000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 2008548000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 215000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | - | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 0 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_ReportableSegmentsMember | 215000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 6852000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | -7067000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration | - | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 1834754000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 59665000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 112798000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_ReportableSegmentsMember | 2007217000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 8399000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | -7067000000 | JPY |
| Revenue IFRS | CurrentYTDDuration | 2008548000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 653450000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 7267000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 1858000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 662575000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -24704000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | -48000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration | 637823000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 562875000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 6608000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 2357000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 571840000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -28873000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -79000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |